Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Guam Technology Journal.
Press releases published on August 26, 2025
IAV Group Joins SDVerse to Accelerate Software Innovation and Drive the Future of Mobility
GlobeNewswire
·
August 26, 2025
DETROIT, Aug. 26, 2025 (GLOBE NEWSWIRE) -- IAV Group (“IAV”), a global leader in automotive engineering specializing in tech-driven, software-defined solutions, today announced it has joined SDVerse − the automotive industry’s first B2B marketplace …
Foresight: Continental and Eye-Net Collaborate to Enhance Road Safety Systems
GlobeNewswire
·
August 26, 2025
The project will evaluate the integration of Eye-Net’s advanced safety technology into Continental’s vehicle platforms Ness Ziona, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “ …
Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform
GlobeNewswire
·
August 26, 2025
– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months after Firefly announced its acceptance into the NVIDIA …
Global CAR T-Cell Therapy Market Set to Reach USD 29 Billion by 2029 | MarketsandMarkets™
GlobeNewswire
·
August 26, 2025
Delray Beach, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell Therapy market, valued at US$3.7 billion in 2023, stood at US$5.5 billion in 2024 and is projected to advance at a resilient CAGR of 39.6% from 2024 to 2029, culminating in a …
Altimmune to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will …
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
GlobeNewswire
·
August 26, 2025
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, …
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
GlobeNewswire
·
August 26, 2025
Data from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamics AVIM therapy drove statistically significant reductions in systolic blood …
Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria
GlobeNewswire
·
August 26, 2025
HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …
Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering
GlobeNewswire
·
August 26, 2025
Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, …
Draganfly Uniquely Positioned to Support Canada’s New $2 Billion Military Commitment to Ukraine with Advanced Drone and Tactical Capabilities
GlobeNewswire
·
August 26, 2025
Saskatoon, SK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an industry-leading developer of drone solutions and systems, today provided insight into its unique positioning to …
Draganfly stratégiquement positionnée pour soutenir le nouvel engagement militaire de 2 milliards de dollars du Canada envers l’Ukraine grâce à ses capacités avancées en drones et tactiques
GlobeNewswire
·
August 26, 2025
Saskatoon, SK, 26 août 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ : DPRO) (CSE : DPRO) (FSE : 3U8) (« Draganfly » ou la « Société »), un développeur de premier plan de solutions et systèmes de drones, a annoncé aujourd’hui sa position unique pour …
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire
·
August 26, 2025
WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative …
Kraig Biocraft Laboratories Accelerates Operations into Two Rearing Centers in One of Southeast Asia's Premier Silk-Producing Regions
GlobeNewswire
·
August 26, 2025
ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that its two recently established rearing centers, located in the …
Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
August 26, 2025
MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 8, 2025 …
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
GlobeNewswire
·
August 26, 2025
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile …
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
GlobeNewswire
·
August 26, 2025
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score U.S. regulatory submission …
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
GlobeNewswire
·
August 26, 2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Cantor …
Syndax Announces Participation in September Investor Conferences
GlobeNewswire
·
August 26, 2025
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of …
Climb Channel Solutions Partners with Coro to Enhance Cybersecurity Solutions
GlobeNewswire
·
August 26, 2025
EATONTOWN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB), is excited to announce a strategic partnership with …
EyePoint Announces Participation at Upcoming Investor Conferences
GlobeNewswire
·
August 26, 2025
WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …